Solesence, Inc. Q4 2025 Earnings Call Insights

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: 1 day ago

0mins

SLSN+13.28%

Should l Buy SLSN?

Source: seekingalpha

Financial Performance Overview: Solesence reported Q4 2025 revenue of $12.5 million and gross profit of $3.4 million, with a gross margin of 27%, reflecting financial pressure due to transition costs and operational inefficiencies from facility consolidation, resulting in a net income of $163,000.
Strategic Plan Announcement: CEO Kevin Cureton emphasized that 2026 will be an execution-focused year with the launch of the 'Transform and Transcend' initiative, aimed at enhancing product design, labor efficiency, and inventory control to achieve profitable growth, which is expected to bolster the company's competitive position in the market.
Leadership Changes: The company appointed Laura Riffner as CFO in September 2025 and added Yoolie Park as Vice President of Brand Partnerships, reflecting a strategic focus on leveraging new leadership to drive profitable growth and effective execution of the company's plans.
Future Outlook: CFO Riffner set a 30% gross margin target for 2026 and anticipates improving free cash flow through working capital actions, despite facing near-term pressures from changes in customer order patterns and weak sell-through from a large mass-market customer.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy SLSN?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on SLSN

About SLSN

Solesence, Inc., formerly Nanophase Technologies Corporation, provides healthcare solutions across beauty and life science categories. It is a developer and manufacturer of clean, inclusive, mineral-based skincare and makeup products. The Company partners with global and indie brands, leveraging its proprietary Active Stress Defense technology suite (Original Active Stress Defense, Kleair, and Bloom) to bring environmental protection beauty products to market via over a dozen market-ready offerings that embrace self-expression, health care, and self-care across skin care and color cosmetic categories. It also offers custom development, with turnkey options available across all paths to market. The Company’s products are formulated using its own mineral sunscreen actives, which are produced in its Chicagoland facility where it has been producing sunscreen actives, including the zinc oxide sunscreen active.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Solesence Q4 Financial Highlights

1 day agoseekingalpha

Slight Revenue Decline: Solesence reported Q4 revenue of $12.5 million, a 0.6% year-over-year decrease, indicating slight fluctuations in market demand that may impact future sales strategies and market positioning.
Significant Gross Profit Increase: The gross profit for Q4 reached $3.4 million, up 21.4% from $2.8 million in the same period of 2024, demonstrating positive progress in cost control and product pricing, thereby enhancing profitability.
Improved Gross Margin: The gross margin in Q4 was 27%, a 5 percentage point increase from 22% in 2024, reflecting the company's success in operational efficiency and product mix optimization, which may attract more investor interest.
Net Income Turnaround: Q4 net income was approximately $0.2 million, compared to a net loss of $0.6 million in the same period of 2024, indicating a significant improvement in profitability that could bolster market confidence and support future growth plans.